These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32968482)

  • 1. Recent advances in managing overactive bladder.
    Araklitis G; Baines G; da Silva AS; Robinson D; Cardozo L
    F1000Res; 2020; 9():. PubMed ID: 32968482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
    Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN
    Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating vibegron for the treatment of overactive bladder.
    Rechberger T; Wróbel A
    Expert Opin Pharmacother; 2021 Jan; 22(1):9-17. PubMed ID: 32993398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
    Chen JV; Klein TM; Nesheim J; Mudd PN
    J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vibegron, a Novel Potent and Selective β
    Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
    Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vibegron: a β
    Paton DM
    Drugs Today (Barc); 2021 Aug; 57(8):507-517. PubMed ID: 34405208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirabegron for the treatment of overactive bladder.
    Gras J
    Drugs Today (Barc); 2012 Jan; 48(1):25-32. PubMed ID: 22384458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?
    Fogaing C; Mossa AH; Campeau L
    Curr Urol Rep; 2020 Oct; 21(12):49. PubMed ID: 33090278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirabegron for overactive bladder syndrome.
    Drug Ther Bull; 2013 Aug; 51(8):90-2. PubMed ID: 23949821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A drug safety evaluation of mirabegron in the management of overactive bladder.
    Robinson D; Thiagamoorthy G; Cardozo L
    Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vibegron for the treatment of overactive bladder: a comprehensive update.
    Gleicher S; Sebesta EM; Reynolds WS; Dmochowski R
    Expert Opin Pharmacother; 2022 Sep; 23(13):1479-1484. PubMed ID: 36124780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
    Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
    BJU Int; 2020 May; 125(5):709-717. PubMed ID: 31991511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.
    Wada N; Mizunaga M; Abe N; Miyauchi K; Kobayashi S; Ohtani M; Tsunekawa R; Nagabuchi M; Morishita S; Ohyama T; Yamaguchi S; Iuchi H; Noda T; Saga Y; Motoya T; Kawakami N; Nishihara M; Numata A; Kakizaki H
    World J Urol; 2024 Mar; 42(1):113. PubMed ID: 38431689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].
    Rechberger T; Kulik-Rechberger B; Miotła P; Wróbel A
    Ginekol Pol; 2014 Mar; 85(3):214-9. PubMed ID: 24783434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials.
    Shi H; Chen H; Zhang Y; Cui Y
    Neurourol Urodyn; 2020 Jun; 39(5):1255-1263. PubMed ID: 32421908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.
    Giarenis I; Robinson D; Cardozo L
    Drugs; 2015 Oct; 75(15):1707-13. PubMed ID: 26323339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.
    Dai R; Deng C
    World J Urol; 2024 May; 42(1):316. PubMed ID: 38736011
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vibegron (Gemtesa) for overactive bladder.
    Med Lett Drugs Ther; 2021 May; 63(1623):67-69. PubMed ID: 33976098
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.